Prosecution Insights
Last updated: November 15, 2026
Application No. 18/270,740

Guide RNA Designs and Complexes for Tracr-less Type V Cas Systems

Non-Final OA §103§112§DP
Filed
Jul 03, 2023
Priority
Jan 05, 2021 — provisional 63/133,942 +1 more
Examiner
TRAN, CHRISTINA L
Art Unit
1637
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Horizon Discovery Limited
OA Round
1 (Non-Final)
50%
Grant Probability
Moderate
1-2
OA Rounds
97%
With Interview

Examiner Intelligence

Grants 50% of resolved cases
50%
Career Allowance Rate
33 granted / 66 resolved
-10.0% vs TC avg
Strong +47% interview lift
Without
With
+47.0%
Interview Lift
resolved cases with interview
Typical timeline
Avg Prosecution
49 currently pending
Career history
118
Total Applications
across all art units

Office Action

§103 §112 §DP
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . DETAILED ACTION Applicant's preliminary amendment filed on April 24, 2026 is acknowledged. Claims 3-17, 20, 21, 25, 26, 29-33, 35-43, 45-50, 52, 55, 58-63, 65-71, 73, 74, and 76-97 have been canceled. Claims 1, 2, 18, 19, 22-24, 27, 28, 34, 44, 51, 53, 54, 56, 57, 64, 72, and 75 are pending. Election/Restrictions Applicant’s election without traverse of Group I (claims 1, 2, 18, 19, 22-24, 27, 28, 34, 44, 51, 53, 54, 56, and 57) in the reply filed on April 24, 2026 is acknowledged. Claims 64, 72, and 75 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected invention, there being no allowable generic or linking claim. Election was made without traverse in the reply filed on April 24, 2026. Claims 1, 2, 18, 19, 22-24, 27, 28, 34, 44, 51, 53, 54, 56, and 57 are examined on the merits herein. Priority PNG media_image1.png 46 468 media_image1.png Greyscale Information Disclosure Statement The information disclosure statement (IDS) submitted on July 10, 2023, April 4, 2025, and February 27, 2026 is in compliance with the provisions of 37 CFR 1.97. Accordingly, the information disclosure statement is being considered by the examiner. The information disclosure statements filed April 4, 2025 and February 27, 2026 fail to comply with the provisions of 37 CFR 1.98(a)(4) because it lacks the appropriate size fee assertion. It has been placed in the application file, but the information referred to therein has not been considered as to the merits. Drawings The drawings were received on July 3, 2023. The drawings are objected to because 37 CFR 1.84 (u)(1) states “View numbers must be preceded by the abbreviation "FIG."”. In addition, Figures 1B, 1C, 1D, 1E, 1G, 2A, 2B, 3A, 3B, 4C-4F, 5A, 5C, 8B-8K are blurry and difficult to read. Furthermore, it is difficult to differentiate between the shadings in the bar graphs for Figures 2A, 2B, 3A, 3B, 4A, 4B, 5A, 5B, 5C, 6, 7A, 7B, 8A, 9, and 10. Corrected drawing sheets in compliance with 37 CFR 1.121(d) are required in reply to the Office action to avoid abandonment of the application. Any amended replacement drawing sheet should include all of the figures appearing on the immediate prior version of the sheet, even if only one figure is being amended. The figure or figure number of an amended drawing should not be labeled as “amended.” If a drawing figure is to be canceled, the appropriate figure must be removed from the replacement sheet, and where necessary, the remaining figures must be renumbered and appropriate changes made to the brief description of the several views of the drawings for consistency. Additional replacement sheets may be necessary to show the renumbering of the remaining figures. Each drawing sheet submitted after the filing date of an application must be labeled in the top margin as either “Replacement Sheet” or “New Sheet” pursuant to 37 CFR 1.121(d). If the changes are not accepted by the examiner, the applicant will be notified and informed of any required corrective action in the next Office action. The objection to the drawings will not be held in abeyance. Specification Applicant is reminded of the proper language and format for an abstract of the disclosure. The abstract should be in narrative form and generally limited to a single paragraph on a separate sheet within the range of 50 to 150 words in length. The abstract should describe the disclosure sufficiently to assist readers in deciding whether there is a need for consulting the full patent text for details. The language should be clear and concise and should not repeat information given in the title. It should avoid using phrases which can be implied, such as, “The disclosure concerns,” “The disclosure defined by this invention,” “The disclosure describes,” etc. In addition, the form and legal phraseology often used in patent claims, such as “means” and “said,” should be avoided. The abstract of the disclosure is objected to because the abstract is less than 50 words in length and the abstract states "A novel gRNA-ligand binding complex is provided." The term “novel” is inherently evaluative and subjective, and not objective and descriptive, as required by MPEP § 608.01(b). A corrected abstract of the disclosure is required and must be presented on a separate sheet, apart from any other text. See MPEP § 608.01(b). The disclosure is objected to because it contains an embedded hyperlink and/or other form of browser-executable code. Applicant is required to delete the embedded hyperlink and/or other form of browser-executable code; references to websites should be limited to the top-level domain name without any prefix such as http:// or other browser-executable code. See MPEP § 608.01. See e.g., [00111] and [00159]. Claim Objections Claims 1, 28, 44, 51, and 56 are objected to because of the following informalities: Claims 1 and 51 have periods within each claim at the bullet points. See MPEP 608.01(m). Claim 28 recites in part “end of gRNA” and should recite “end of the gRNA” (emphasis added). Claim 44 recites abbreviations which should be clearly written out at their first occurrence in the claim and should be followed by the abbreviation in parentheses. Claim 56 recites in part “The base editing complex of any claim 51” and should recite “The base editing complex of claim 51”. Appropriate correction is required. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claim 44 is rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. A broad range or limitation together with a narrow range or limitation that falls within the broad range or limitation (in the same claim) may be considered indefinite if the resulting claim does not clearly set forth the metes and bounds of the patent protection desired. See MPEP § 2173.05(c). In the present instance, claim 44 recites the broad recitation “Anti-His Tag”, and the claim also recites “(6H7)” which is the narrower statement of the range/limitation. The claim(s) are considered indefinite because there is a question or doubt as to whether the feature introduced by such narrower language is (a) merely exemplary of the remainder of the claim, and therefore not required, or (b) a required feature of the claims. Claim 44 contains the trademark/trade name SNAP-Tag. Where a trademark or trade name is used in a claim as a limitation to identify or describe a particular material or product, the claim does not comply with the requirements of 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph. See Ex parte Simpson, 218 USPQ 1020 (Bd. App. 1982). The claim scope is uncertain since the trademark or trade name cannot be used properly to identify any particular material or product. A trademark or trade name is used to identify a source of goods, and not the goods themselves. Thus, a trademark or trade name does not identify or describe the goods associated with the trademark or trade name. In the present case, the trademark/trade name is used to identify/describe a protein tag and, accordingly, the identification/description is indefinite. Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention. Claims 1, 18, 19, 22, 23, 44, 51, 53, 54, 56, and 57 are rejected under 35 U.S.C. 103 as being unpatentable over Smargon et al. (US 2017/0211142) in view of Kim (US 2021/0130827). Regarding claims 1, 18, 19, 22, 23, 44, 51, 53, 54, 56, and 57, Smargon et al. teaches that when the CRISPR protein is a Class 2 Type VI-B effector, a tracrRNA is not required. In an engineered system of the invention, the direct repeat may encompass naturally-occurring sequences or non-naturally occurring sequences and can be 36 nt in length. In some embodiments, a direct repeat of the invention can include synthetic nucleotide sequences inserted between the 5′ and 3′ ends of naturally occurring direct repeat. Furthermore, a direct repeat may include insertions of nucleotides such as an aptamer or sequences that bind to an adapter protein (for association with functional domains) [0212]. Smargon et al. also teaches that Cas13b function is robust to 5′ or 3′ extensions of the crRNA and to extension of the crRNA loop. It is therefore envisages that MS2 loops and other recruitment domains can be added to the crRNA without affecting complex formation and binding to target transcripts [0352]. However, Smargon et al. does not teach a Type V Cas protein. Smargon et al. does not explicitly teach that the ligand binding moiety is directly bound to the 3’ end of the gRNA (claim 18) or the 5’ end of the gRNA (claim 19). Smargon et al. also does not teach a Type V Cas protein comprising an active RuvC domain or a deactivated RuvC domain (claims 53 and 54). Smargon et al. does not teach an effector attached to a ligand wherein the effector is a deaminase (claims 56 and 57). Kim teaches Type V CRISPR-Cas effector proteins, deaminases, and fusion and recruiting nucleic acid constructs thereof [0002]. The Type V CRISPR-Cas effector protein may be a Cas12a effector protein, Cas12a enzymes use a single guide RNA (gRNA, CRISPR array, crRNA), and Cas12a relies on a single RuvC domain to cleave both DNA strands [0102]. Kim teaches that a “recruiting guide nucleic acid” or “recruiting guide RNA” is a guide nucleic acid that comprises an RNA recruiting motif wherein the RNA recruiting motif may be linked to the 3′ end or the 5′ end of the recruiting guide nucleic acid. An RNA recruiting motif may be any RNA motif capable of being recognized by an affinity polypeptide (e.g., an MS2 phage operator stem-loop and an affinity polypeptide of MS2 Coat Protein (MCP)) [0118]. Kim teaches base editing nucleic acid constructs comprising: (a) a Type V CRISPR-Cas fusion protein comprising a Type V CRISPR-Cas effector protein fused to a peptide tag; (b) a deaminase fusion protein comprising a deaminase fused to an affinity polypeptide that is capable of binding to the peptide tag; and (c) a guide nucleic acid [0088]. Kim teaches that the Type V CRISPR-Cas effector protein may comprise a mutation in its nuclease active site (e.g., RuvC) or the Type V CRISPR-Cas effector protein having a mutation in its nuclease active site may have impaired activity or reduced activity. In some embodiments, a Type V CRISPR-Cas effector protein having a mutation in its nuclease active site may have impaired activity or reduced activity as compared to the same Type V CRISPR-Cas effector protein without the mutation, e.g., a nickase such as a Cas12a nickase [0100]. It would have been obvious for one of ordinary skill in the art before the effective filing date of the claimed invention to modify the gRNA-ligand binding complex of Smargon et al. wherein the Cas association region is capable of retaining association with an RNA binding domain of a Type V Cas protein because Smargon et al. taught a gRNA-ligand binding complex wherein the complex comprises a gRNA and a ligand binding moiety and Kim taught Type V CRISPR-Cas effector proteins, deaminases, and fusion and recruiting nucleic acid constructs thereof. One of ordinary skill in the art would have made such a modification because it would have amounted to a simple substitution of one known element for another to obtain predictable results. It would have been obvious for one of ordinary skill in the art before the effective filing date of the claimed invention to modify the gRNA-ligand binding complex of Smargon et al. and Kim wherein the ligand binding moiety is directly bound to the 3’ end of the gRNA or the 5’ end of the gRNA because Smargon et al. taught a gRNA-ligand binding complex wherein the complex comprises a gRNA and a ligand binding moiety and Kim taught that an RNA recruiting motif may be linked to the 3′ end or the 5′ end of the recruiting guide nucleic acid. Kim also taught that an RNA recruiting motif may be any RNA motif capable of being recognized by an affinity polypeptide (e.g., an MS2 phage operator stem-loop and an affinity polypeptide of MS2 Coat Protein (MCP)). One of ordinary skill in the art would have made such a modification because it would have amounted to combining known prior art elements to yield predictable results. It would have been obvious for one of ordinary skill in the art before the effective filing date of the claimed invention to modify the base editing complex of Kim wherein the complex comprises the gRNA-ligand binding complex of claim 1 and a Type V Cas protein because Kim taught base editing nucleic acid constructs comprising: (a) a Type V CRISPR-Cas fusion protein comprising a Type V CRISPR-Cas effector protein fused to a peptide tag; (b) a deaminase fusion protein comprising a deaminase fused to an affinity polypeptide that is capable of binding to the peptide tag; and (c) a guide nucleic acid [0088]. Kim also taught that the Type V CRISPR-Cas effector protein may comprise a mutation in its nuclease active site (e.g., RuvC) or the Type V CRISPR-Cas effector protein having a mutation in its nuclease active site may have impaired activity or reduced activity and Smargon et al. taught a gRNA-ligand binding complex wherein the complex comprises a gRNA and a ligand binding moiety. One of ordinary skill in the art would have made such a modification because it would have amounted to combining known prior art elements to yield predictable results. Claim 2 is rejected under 35 U.S.C. 103 as being unpatentable over Smargon et al. (US 2017/0211142) in view of Kim (US 2021/0130827) as applied to claims 1, 18, 19, 22, 23, 44, 51, 53, 54, 56, and 57 above, and further in view of Jin et al. (US 2018/0327784; reference cited by Applicant). Regarding claim 2, the teachings of Smargon et al. and Kim are discussed above. However, Smargon et al. and Kim do not teach wherein at least one of the gRNA and the ligand binding moiety comprises at least one modification. Jin et al. teaches a system for targeted gene editing [abstract]. Jin et al. teaches that the RNA scaffold may include one or more modifications. Such modifications may include inclusion of at least one non-naturally occurring nucleotide, or a modified nucleotide, or analogs thereof. Modified nucleotides may be modified at the ribose, phosphate, and/or base moiety. In a preferred embodiment these modifications are made to the RNA components, e.g. the guide RNA sequence [0073]. It would have been obvious for one of ordinary skill in the art before the effective filing date of the claimed invention to modify the gRNA-ligand binding complex of Smargon et al. and Kim wherein at least one of the gRNA and the ligand binding moiety comprises at least one modification because Smargon et al. taught a gRNA-ligand binding complex wherein the complex comprises a gRNA and a ligand binding moiety and Jin et al. taught that the RNA scaffold may include one or more modifications such as inclusion of at least one non- naturally occurring nucleotide, or a modified nucleotide, or analogs thereof. Modified nucleotides may be modified at the ribose, phosphate, and/or base moiety and in a preferred embodiment these modifications are made to the guide RNA sequence. One of ordinary skill in the art would have made such a modification because it would have amounted to combining known prior art elements to yield predictable results. Claims 24, 27, 28, and 34 are rejected under 35 U.S.C. 103 as being unpatentable over Smargon et al. (US 2017/0211142) in view of Kim (US 2021/0130827) as applied to claims 1, 18, 19, 22, 23, 44, 51, 53, 54, 56, and 57 above, and further in view of Zalatan et al. (Cell 2015; reference cited by Applicant). Regarding claims 24, 27, 28, and 34, the teachings of Smargon et al. and Kim are discussed above. However, Smargon et al. and Kim do not teach wherein the gRNA-ligand binding complex comprises the linker and the ligand binding moiety is bound to the gRNA through the linker (claim 24). Smargon et al. and Kim do not teach wherein the linker is bound to the 3’ end of the gRNA (claim 27) or bound to the 5’ end of the gRNA (claim 28). Smargon et al. and Kim also do not teach wherein the complex comprises two linkers and the ligand binding moiety is located between the first and second linker (claim 34). Zalatan et al. teaches a single RNA hairpin domain to the 3’ end of the sgRNA connected by a two-base linker [page 341, left column, second full paragraph]. Further, one, two, or three MS2 RNA hairpins were introduced to the 3’ end of the sgRNA [page 341, right column, third full paragraph]. Zalatan et al. also constructed an alternative RNA design in which double-stranded linkers were inserted between the two repeats of the recruitment hairpins to enforce stable, local hairpin formation [page 341, right column, fourth full paragraph]. Zalatan et al. also teaches that scRNA designs with recruitment sequences attached to the 5’ end of the sgRNA gave no significant activation [page 341, right column, first paragraph]. It would have been obvious for one of ordinary skill in the art before the effective filing date of the claimed invention to modify the gRNA-ligand binding complex of Smargon et al. and Kim wherein the ligand binding moiety is bound to the gRNA through the linker (claim 24), wherein the linker is bound to the 3’ end of the gRNA (claim 27) or the 5’ end of the gRNA (claim 28), and wherein the complex comprises two linkers and the ligand binding moiety is located between the first and second linker (claim 34) because Smargon et al. taught a gRNA-ligand binding complex wherein the complex comprises a gRNA and a ligand binding moiety and Zalatan et al. taught a single RNA hairpin domain to the 3’ end of the sgRNA connected by a two-base linker. Zalatan et al. also taught that one, two, or three MS2 RNA hairpins were introduced to the 3’ end of the sgRNA and also constructed an alternative RNA design in which double-stranded linkers were inserted between the two repeats of the recruitment hairpins to enforce stable, local hairpin formation. Zalatan et al. also taught scRNA designs with recruitment sequences attached to the 5’ end of the sgRNA. One of ordinary skill in the art would have made such a modification because it would have amounted to combining known prior art elements to yield predictable results. Double Patenting The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b). The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13. The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer. Claims 1, 2, 18, 19, 22-24, 27, 28, 34, 44, 51, 53, 54, 56, and 57 are provisionally rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1, 5, 7, 11, 13, 17-19, 21, 25, 31, 35-37, 40, and 44 of copending Application No. 18/270,879 (reference application). Although the claims at issue are not identical, they are not patentably distinct from each other because the claims overlap in scope. The instant application is drawn to a gRNA-ligand binding complex wherein the gRNA-ligand binding complex comprises a gRNA and a ligand binding moiety and a base editing complex comprising the gRNA-ligand binding complex of claim 1 and a Type V Cas protein. Copending application ‘879 is drawn to a method for genetically modifying a cell by base editing comprising introduction into the cell and/or expression in the cell of i) a sequence-targeting protein; ii) an RNA-ligand binding complex comprising a guide RNA and a ligand binding moiety; and iii) two or more effector proteins. Copending application ‘879 is also drawn to a kit for genetically modifying a cell by base editing. This is a provisional nonstatutory double patenting rejection because the patentably indistinct claims have not in fact been patented. Conclusion No claims are allowed. Any inquiry concerning this communication or earlier communications from the examiner should be directed to CHRISTINA TRAN whose telephone number is (571)270-0550. The examiner can normally be reached M-F 7:30 - 5:00pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Jennifer Dunston can be reached at (571) 272-2916. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /C.T./ Examiner, Art Unit 1637 /Jennifer Dunston/Supervisory Patent Examiner, Art Unit 1637
Read full office action

Prosecution Timeline

Jul 03, 2023
Application Filed
Aug 24, 2026
Non-Final Rejection mailed — §103, §112, §DP (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12781222
OLIGOMER-CONJUGATE COMPLEXES AND THEIR USE
5y 4m to grant Granted Nov 03, 2026
Patent 12753215
ß-AMYLOID CYCLIC RIBONUCLEIC ACID, POLYPEPTIDE, AND APPLICATION THEREOF
4y 8m to grant Granted Oct 06, 2026
Patent 12747438
COMPOSITIONS AND METHODS FOR REPROGRAMMING AGE-RESTRICTED NON-NEURONAL CELLS
4y 5m to grant Granted Sep 29, 2026
Patent 12721858
DOUBLE-STRANDED OLIGONUCLEOTIDE TARGETING DKK1 GENE, CONSTRUCT INCLUDING SAME, AND HAIR LOSS PREVENTION OR HAIR GROWTH COMPOSITION CONTAINING SAME
5y 1m to grant Granted Sep 01, 2026
Patent 12723247
METHODS FOR INHIBITION OF HAO1 (HYDROXYACID OXIDASE 1 (GLYCOLATE OXIDASE)) GENE EXPRESSION
4y 7m to grant Granted Sep 01, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
50%
Grant Probability
97%
With Interview (+47.0%)
Low
PTA Risk
Based on 66 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month